Table 2 Treatment effects (intention-to-treat analysis)
Outcome | ATS, mean (SD) (n = 49) | Waiting, mean (SD) (n = 49) | Effect size, Cohen’s d (95% CI) | p value |
|---|---|---|---|---|
Asthma Quality of Life Questionnaire | ||||
Overall | 0.63 (0.67) | 0.07 (0.63) | 0.86 (0.43 to 1.28) | 0.001 |
Symptoms | 0.60 (0.87) | 0.03 (0.72) | 0.71 (0.28 to 1.12) | 0.006 |
Activity limitation | 0.74 (0.76) | 0.10 (0.76) | 0.84 (0.41 to 1.25) | 0.001 |
Emotional function | 0.57 (0.85) | 0.05 (0.91) | 0.58 (0.17 to 0.99) | 0.013 |
Environmental exposure | 0.56 (1.03) | 0.15 (0.84) | 0.43 (0.02 to 0.84) | 0.079 |
Lung function | ||||
FEV1, L | − 0.01 (0.32) | 0.05 (0.29) | − 0.18 (− 0.58 to 0.23) | 0.471 |
FVC, L | 0.02 (0.33) | 0.03 (0.30) | − 0.06 (− 0.46 to 0.35) | 0.805 |
FEV1/FVC, %‡ | 0.00 (0.09) | 0.01 (0.10) | −0.01 (− 0.41 to 0.40) | 0.385 |
Inhaled glucocorticoids, μg per week†‡ | 6.96 (189.08) | −8.35 (168.63) | 0.09 (−0.31 to 0.48) | 0.581 |
Asthma Control Test‡ | 1.57 (4.06) | −0.51 (3.78) | 0.53 (0.12 to 0.94) | 0.048 |
Peak flow (morning), L/min‡ | 8.27 (46.30) | 5.42 (44.18) | 0.06 (−0.35 to 0.47) | 0.519 |
Peak flow (evening), L/min‡ | 9.24 (50.66) | 9.71 (44.19) | −0.01 (− 0.42 to 0.40) | 0.943 |
Days without asthma exacerbation per week‡ | 0.20 (1.27) | 0.05 (0.98) | 0.12 (−0.29 to 0.53) | 0.758 |